Currently out of the existing stock ratings of Glen Santangelo, 203 are a BUY (69.28%), 82 are a HOLD (27.99%), 8 are a SELL (2.73%).

Glen Santangelo

Work Performance Price Targets & Ratings Chart

Analyst Glen Santangelo, currently employed at BARCLAYS, carries an average stock price target met ratio of 57.32% that have a potential upside of 25.57% achieved within 247 days.

Glen Santangelo’s has documented 575 price targets and ratings displayed on 55 stocks. The coverage is on Healthcare, Consumer Defensive, Technology, Consumer Cyclical sectors.

Most recent stock forecast was given on TEVA, Teva Pharma Industries Ltd ADR at 15-Oct-2026.

Wall Street Analyst Glen Santangelo

Analyst best performing recommendations are on AMRX (AMNEAL PHARMACEUTICALS).
The best stock recommendation documented was for HIMS (HIMS HERS HEALTH) at 2/25/2026. The price target of $25 was fulfilled within 14 days with a profit of $9.18 (58.03%) receiving and performance score of 41.45.

Average potential price target upside

of $134.52 (84.67%) on INO (INOVIO PHARMACEUTICALS).
of $80.79 (19.5%) on MCK (MCKESSON).
of $34.29 (52.59%) on COR (CENCORA).

ABC AmerisourceBergen BBLN Babylon Holdings Ltd CAH Cardinal Health DOCS Doximity DPLO Diplomat Pharmacy HCAT Health Catalyst HMSY HMS Holdings Corp HQY HealthEquity HSIC Henry Schein MCK McKesson MDSO Medidata Solutions PDCO Patterson Companies PGNY Progyny PHR Phreesia RAD Rite Aid TDOC Teladoc TRHC Tabula Rasa HealthCare WBA Walgreens Boots Alliance XRAY Dentsply Sirona ALGN Align Technology CVS CVS Health Corp GDRX Goodrx Holdings RCM R1 RCM ACCD Accolade AMWL American Well Corp ATHN athenahealth CHNG Change Healthcare HIMS Hims Hers Health DH Definitive Healthcare Corp TALK Talkspace VCRA Vocera Communications TEVA Teva Pharma Industries Ltd ADR VTRS Viatris SCPH Scpharmaceuticals AMPH Amphastar P VRCA Verrica Pharmaceuticals BHC Bausch Health Companies COLL Collegium Pharmaceutical ELAN Elanco Animal Health PCRX Pacira Pharmaceuticals SDC SmileDirectClub PHAT Phathom Pharmaceuticals NVST Envista Holdings Corp INO Inovio Pharmaceuticals INOV Inovalon Holdings OPTN OptiNose RVLP RVL Pharmaceuticals PLC ALVO Alvotech AMRX Amneal Pharmaceuticals COR Cencora IDXX IDEXX Laboratories INDV Indivior PLC WW WW International XERS Xeris Pharmaceuticals ZTS Zoetis

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Charles Rhyee (TD COWEN)

Buy Since 27-Feb-2018

$215

$40.04 (22.89%)

$187

3 years 2 months 16 days ago
(07-Aug-2023)

15/16 (93.75%)

$28.91 (15.54%)

636

Please subscribe to see extended stock data

Ricky Goldwasser (MORGAN STANLEY)

Hold Since 27-May-2022

$190

$15.04 (8.60%)

$176

3 years 2 months 20 days ago
(03-Aug-2023)

12/12 (100%)

$-0.86 (-0.45%)

392

Please subscribe to see extended stock data

Michael Cherny (LEERINK)

Buy Since 11-Oct-2022

$215

$40.04 (22.89%)

$200

3 years 2 months 20 days ago
(03-Aug-2023)

7/10 (70%)

$24.14 (12.65%)

211

Please subscribe to see extended stock data

Eric Coldwell (BAIRD)

Buy Since 05-Aug-2021

$220

$45.04 (25.74%)

$213

3 years 2 months 20 days ago
(03-Aug-2023)

11/17 (64.71%)

$29.14 (15.27%)

326

Please subscribe to see extended stock data

Erin Wright (MORGAN STANLEY)

$190

$15.04 (8.60%)

3 years 2 months 20 days ago
(03-Aug-2023)

9/9 (100%)

$-0.86 (-0.45%)

440

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Glen Santangelo most bullish on?

Potential upside of $149.64 has been obtained for IDXX (IDEXX LABORATORIES)

Which stock is Glen Santangelo most reserved on?

Potential downside of -$30.12 has been obtained for MCK (MCKESSON)

What Year was the first public recommendation made by Glen Santangelo?

On 2008